{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/erectile-dysfunction/how-up-to-date-is-this-topic/changes/","result":{"pageContext":{"chapter":{"id":"6f8d7396-341b-5cdb-9ab7-11d371aecf1b","slug":"changes","fullItemName":"Changes","depth":2,"htmlHeader":"<!-- begin field 1910dcd5-1027-4cf6-91c7-5722b3cd600b --><h2>Changes</h2><!-- end field 1910dcd5-1027-4cf6-91c7-5722b3cd600b -->","summary":null,"htmlStringContent":"<!-- begin item eaa8ec35-5748-445a-a17a-c649bdecaab6 --><!-- begin field 440c2554-79f5-488b-8487-f08c5c854f75 --><p><strong>July 2020 </strong>— minor update. Additional information regarding prostate cancer as a cause of erectile dysfunction has been included.</p><p><strong>August 2019</strong> — minor update. Topic has been updated in line with the British Society for Sexual Medicine (BSSM), 2017, <em>Guidelines on the management of erectile dysfunction </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/erectile-dysfunction/references/\">BSSM, 2017</a>].</p><p><strong>December 2017</strong> — reviewed. A literature search was conducted in October 2017 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of this topic. No major changes to clinical recommendations have been made. However, a prescribing information section for avanafil (Spedra<sup>®</sup>) has been added and the topic has been restructured.</p><!-- end field 440c2554-79f5-488b-8487-f08c5c854f75 --><!-- end item eaa8ec35-5748-445a-a17a-c649bdecaab6 -->","topic":{"id":"5bdc98b8-cec1-551c-a1ea-d279c1d4a789","topicId":"a255a0a6-1216-4961-a8d2-0841d9ddf8fe","topicName":"Erectile dysfunction","slug":"erectile-dysfunction","lastRevised":"Last revised in July 2020","chapters":[{"id":"60de3c56-e8f8-5ed1-af6c-079fbfc5297a","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"1390eb84-15de-5511-a888-7aa10c5f380e","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"6f0e3524-4bd9-524b-b0c7-5df8463a2632","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"6f8d7396-341b-5cdb-9ab7-11d371aecf1b","slug":"changes","fullItemName":"Changes"},{"id":"7273623f-46a6-55a9-b20f-3174d857bb0b","slug":"update","fullItemName":"Update"}]},{"id":"954f3dd9-902d-5807-89cb-b68e9a352975","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"4dbc024b-ad9c-5c73-975f-44d47f56c8db","slug":"goals","fullItemName":"Goals"},{"id":"3c8ab157-63cf-5e79-95c8-8d533751d80b","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"c87478c5-0e05-5e5e-aff4-92c6bd965c7e","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"7aad46cb-3cd1-586a-9eb7-5b41fb304896","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"792aba04-631e-555e-8bf8-2c58ec675d8d","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"19da5bcc-2817-5766-9335-d7974d14f3c4","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"9a1a9a32-e4af-5cb5-83a9-c382b1ee5d40","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"ecd0b9da-d509-587d-9c32-4e2828d198af","slug":"definition","fullItemName":"Definition"},{"id":"a0eac8e3-a0a4-5026-870e-24f5a5597b63","slug":"causes","fullItemName":"Causes"},{"id":"1e4fb7fb-80f2-58a9-9f0a-cd2a06bd58f5","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"8f1a78ac-cb2e-5627-aaf2-9eddf7d19863","slug":"prevalence","fullItemName":"Prevalence"},{"id":"fd7eccbd-c104-54ec-aa7e-7b5d8c806ded","slug":"prognosis","fullItemName":"Prognosis"},{"id":"3dbe567c-f646-542c-a649-49c5e0a2e1d8","slug":"complications","fullItemName":"Complications"}]},{"id":"a7b9bdc4-1390-5184-aa4d-a331be735168","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"bdb32096-c2e0-55ac-b935-a61204406095","slug":"assessment","fullItemName":"Assessment"}]},{"id":"7b089806-f4ac-58ac-a788-629e509b4868","fullItemName":"Management","slug":"management","subChapters":[{"id":"09f9cf76-1bbb-5d37-8bf8-9ed3fd4a9b64","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"92e38517-29a0-5e5f-8e17-2959aa09e71a","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"0d5ad6d5-d065-5eb5-99c8-b654497d8d19","slug":"phosphodiesterase-5-pde-5-inhibitors","fullItemName":"Phosphodiesterase-5 (PDE-5) inhibitors"}]},{"id":"f021401a-d917-5e2c-b234-816a1108de92","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"c0f733e9-9f61-5807-8fce-90a6aba44893","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"ab85ccb2-6023-521d-b0ed-2cf9647aff63","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"536d66ad-375a-52d4-a2ee-1dfc1ec8a13e","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"d1ea3b0d-cce2-5191-82e1-3149d32c0296","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"c69a15f7-87a5-5513-b5d1-b21a85dd1561","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"1d54146b-d6e9-54f2-885a-74200666af7c","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"04d092eb-cbf9-5bce-9d0d-65e9e5d6ba1b","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"6f0e3524-4bd9-524b-b0c7-5df8463a2632","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"ee508182-7677-546d-be08-7a6b5c5173ef","slug":"previous-changes","fullItemName":"Previous changes","depth":3,"htmlHeader":"<!-- begin field 2ecdde43-6f91-4457-b4fa-af0c91145864 --><h3>Previous changes</h3><!-- end field 2ecdde43-6f91-4457-b4fa-af0c91145864 -->","summary":null,"htmlStringContent":"<!-- begin item 64c57b2b-c837-4d01-8810-34010bddf5a9 --><!-- begin field 17ff591b-48d7-423a-8530-831fd4b5c128 --><p><strong>November 2016</strong> — minor update. The contraindications and interactions sections have been updated to include information that guanylate cyclase stimulators, such as riociguat, are contraindicated in men receiving phosphodiesterase-5-inhibitors (PDE-5 inhibitors), as concomitant use may lead to symptomatic hypotension.</p><p><strong>December 2014 </strong>— minor update. Change to the text with regards to sildenafil to improve clarity.</p><p><strong>November 2014</strong> — minor update. Removal of Selected List Scheme (SLS) status for generic sildenafil products.</p><p><strong>January 2013 </strong> — reviewed. A literature search was conducted in December 2012 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials (RCTs) published since the last revision of the topic. No major changes to clinical recommendations have been made.</p><p><strong>January 2012 </strong>— minor update to clarify the term 'protracted secondary ejaculation' in response to an enquiry. Issued in January 2012.</p><p><strong>July 2011 </strong> — minor update to the treatment of erectile dysfunction to include advice from the Medicines and Healthcare products Regulatory Agency (MHRA) on the use of unlicensed herbal remedies. Issued in September 2011.</p><p><strong>October 2009 </strong>— minor update. A link to the Sexual Dysfunction Association website (<a href=\"http://www.sda.uk.net/\" data-hyperlink-id=\"2c4dceb1-26e7-4889-b7d8-a98e010726c6\">www.sda.uk.net</a>) has been added. Issued in October 2009.</p><p><strong>May 2009 </strong>— minor update to include advice from the MHRA on PDE-5-inhibitors and non-selective alpha-blockers. Issued in June 2009.</p><p><strong>March 2009 </strong>— minor update to include hypopituitarism following traumatic brain injury as a possible cause of erectile dysfunction.</p><p><strong>July to October 2008 </strong>— this is a new CKS topic. The evidence base has been reviewed in detail, and recommendations are clearly justified and transparently linked to the supporting evidence.</p><!-- end field 17ff591b-48d7-423a-8530-831fd4b5c128 --><!-- end item 64c57b2b-c837-4d01-8810-34010bddf5a9 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}